Patents by Inventor Kristian Sass-Oerum
Kristian Sass-Oerum has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240108731Abstract: The invention relates to novel derivatives of Interleukin-22 (IL-22), particularly those comprising a fatty acid covalently attached to an IL-22 protein, and their use in therapy.Type: ApplicationFiled: June 30, 2023Publication date: April 4, 2024Inventors: Kristian SASS-ØRUM, Rasmus JØRGENSEN, Sebastian Beck JØRGENSEN, Henning THØGERSEN, Thomas HOEG-JENSEN, Michael Paolo Bastner SANDRINI
-
Publication number: 20230381320Abstract: The invention relates to novel derivatives of Interleukin-22 (IL-22), particularly those comprising a fatty acid covalently attached to an IL-22 protein, and their use in therapy.Type: ApplicationFiled: June 30, 2023Publication date: November 30, 2023Inventors: Kristian SASS-ØRUM, Rasmus JØRGENSEN, Sebastian Beck JØRGENSEN, Henning THØGERSEN, Thomas HOEG-JENSEN, Michael Paolo Bastner SANDRINI
-
Publication number: 20230364248Abstract: The invention relates to MIC-1 compounds. More specifically it relates to compounds comprising a MIC-1 polypeptide with an N-terminal amino acid extension and a protractor wherein the amino acid extension comprises 3 to 36 amino acid residues and where the MIC-1 polypeptide and the N-terminal amino acid extension together have a calculated pI lower than 6.5. The compounds of the invention have MIC-1 activity. The invention also relates to pharmaceutical compositions comprising such compounds and pharmaceutically acceptable excipients, as well as the medical use of the compounds.Type: ApplicationFiled: December 19, 2022Publication date: November 16, 2023Inventors: Xiang Gao, Xujia Zhang, Hongtao Guan, Henning Thoegersen, Kristian Sass-oerum, Lars Fogh Iversen, Per Noergaard, Sebastian Beck Joergensen, Kristian Tage Hansen, Yi Wang, Kilian Waldemar Conde Frieboes, Birgit Wieczorek
-
Patent number: 11806403Abstract: The invention relates to novel derivatives of Interleukin-22 (IL-22), particularly those comprising a fatty acid covalently attached to an IL-22 protein, and their use in therapy.Type: GrantFiled: May 5, 2022Date of Patent: November 7, 2023Assignee: CytoKi Pharma ApSInventors: Kristian Sass-Ørum, Rasmus Jørgensen, Sebastian Beck Jørgensen, Henning Thøgersen, Thomas Hoeg-Jensen, Michael Paolo Bastner Sandrini
-
Publication number: 20230212245Abstract: The invention relates to MIC-1 compounds. More specifically it relates to compounds comprising a MIC-1 polypeptide and an N-terminal amino acid extension, wherein said extension consists of 3 to 36 amino acid residues and where the compound has a calculated pI lower than 6.5. The compounds of the invention have MIC-1 activity. The invention also relates to pharmaceutical compositions comprising such compounds and pharmaceutically acceptable excipients, as well as the medical use of the compounds.Type: ApplicationFiled: December 19, 2022Publication date: July 6, 2023Inventors: Xujia Zhang, Xiang Gao, Hongtao Guan, Henning Thoegersen, Kristian Sass-oerum, Lars Fogh Iversen, Per Noergaard, Sebastian Beck Joergensen, Kristian Tage Hansen, Yi Wang
-
Publication number: 20220347304Abstract: The invention relates to novel derivatives of Interleukin-22 (IL-22), particularly those comprising a fatty acid covalently attached to an IL-22 protein, and their use in therapy.Type: ApplicationFiled: May 5, 2022Publication date: November 3, 2022Inventors: Kristian SASS-ØRUM, Rasmus Jørgensen, Sebastian Beck Jørgensen, Henning Thøgersen, Thomas Hoeg-Jensen, Michael Paolo Bastner Sandrini
-
Publication number: 20210198331Abstract: The invention relates to MIC-1 compounds. More specifically it relates to compounds comprising a MIC-1 polypeptide and an N-terminal amino acid extension, wherein said extension consists of 3 to 36 amino acid residues and where the compound has a calculated pI lower than 6.5. The compounds of the invention have MIC-1 activity. The invention also relates to pharmaceutical compositions comprising such compounds and pharmaceutically acceptable excipients, as well as the medical use of the compounds.Type: ApplicationFiled: March 8, 2021Publication date: July 1, 2021Inventors: Xujia Zhang, Xiang Gao, Hongtao Guan, Henning Thoegersen, Kristian Sass-Oerum, Lars Fogh Iversen, Per Noergaard, Sebastian Beck Joergensen, Kristian Tage Hansen, Yi Wang
-
Publication number: 20200079829Abstract: The invention relates to MIC-1 compounds. More specifically it relates to compounds comprising a MIC-1 polypeptide with an N-terminal amino acid extension and a protractor wherein the amino acid extension comprises 3 to 36 amino acid residues and where the MIC-1 polypeptide and the N-terminal amino acid extension together have a calculated pI lower than 6.5. The compounds of the invention have MIC-1 activity. The invention also relates to pharmaceutical compositions comprising such compounds and pharmaceutically acceptable excipients, as well as the medical use of the compounds.Type: ApplicationFiled: May 23, 2018Publication date: March 12, 2020Inventors: Xiang Gao, Xujia Zhang, Hongtao Guan, Henning Thoegersen, Kristian Sass-Oerum, Lars Fogh Iversen, Per Noergaard, Sebastian Beck Joergensen, Kristian Tage Hansen, Yi Wang, Kilian Waldemar Conde Frieboes, Birgit Wieczorek
-
Patent number: 10398782Abstract: The invention relates to MIC-1 compounds. More specifically it relates to compounds comprising a MIC-1 polypeptide with an N-terminal amino acid extension and a protractor wherein the amino acid extension comprises 3 to 36 amino acid residues and where the MIC-1 polypeptide and the N-terminal amino acid extension together have a calculated pI lower than 6.5. The compounds of the invention have MIC-1 activity. The invention also relates to pharmaceutical compositions comprising such compounds and pharmaceutically acceptable excipients, as well as the medical use of the compounds.Type: GrantFiled: May 23, 2018Date of Patent: September 3, 2019Assignee: Novo Nordisk A/SInventors: Xiang Gao, Xujia Zhang, Hongtao Guan, Henning Thoegersen, Kristian Sass-Oerum, Lars Fogh Iversen, Per Noergaard, Sebastian Beck Joergensen, Kristian Tage Hansen, Yi Wang, Kilian Waldemar Conde Frieboes, Birgit Wieczorek
-
Publication number: 20190248852Abstract: The invention relates to MIC-1 compounds. More specifically it relates to compounds comprising a MIC-1 polypeptide and an N-terminal amino acid extension, wherein said extension consists of 3 to 36 amino acid residues and where the compound has a calculated pI lower than 6.5. The compounds of the invention have MIC-1 activity. 5 The invention also relates to pharmaceutical compositions comprising such compounds and pharmaceutically acceptable excipients, as well as the medical use of the compounds.Type: ApplicationFiled: May 24, 2017Publication date: August 15, 2019Applicants: Novo Nordisk A/S, Novo Nordisk A/SInventors: Xujia Zhang, Xiang Gao, Hongtao Guan, Henning Thoegersen, Kristian Sass-Oerum, Lars Fogh Iversen, Per Noergaard, Sebastian Beck Joergensen, Kristian Tage Hansen, Yi Wang
-
Publication number: 20180339057Abstract: The invention relates to MIC-1 compounds. More specifically it relates to compounds comprising a MIC-1 polypeptide with an N-terminal amino acid extension and a protractor wherein the amino acid extension comprises 3 to 36 amino acid residues and where the MIC-1 polypeptide and the N-terminal amino acid extension together have a calculated pI lower than 6.5. The compounds of the invention have MIC-1 activity. The invention also relates to pharmaceutical compositions comprising such compounds and pharmaceutically acceptable excipients, as well as the medical use of the compounds.Type: ApplicationFiled: May 23, 2018Publication date: November 29, 2018Inventors: Xiang Gao, Xujia Zhang, Hongtao Guan, Henning Thoegersen, Kristian Sass-Oerum, Lars Fogh Iversen, Per Noergaard, Sebastian Beck Joergensen, Kristian Tage Hansen, Yi Wang, Kilian Waldemar Conde Frieboes, Birgit Wieczorek
-
Patent number: 10124039Abstract: The invention relates to a derivative of a FGF21 protein having a cysteine residue at a position corresponding to position 167, 169, 170, 171, 172, 173, 174, 175 and in particular position 180 or position 181 of mature human FGF21 and derivatives thereof having a side chain attached to this cysteine. The FGF21 derivatives of the invention display high potency towards the FGF receptors. The invention also relates to pharmaceutical compositions comprising such FGF21 derivatives and pharmaceutically acceptable excipients, as well as the medical use of the FGF21 derivatives.Type: GrantFiled: December 21, 2017Date of Patent: November 13, 2018Assignee: Novo Nordisk A/SInventors: Birgit Wieczorek, Tina Moeller Tagmose, Kristian Sass-Oerum, Birgitte Andersen, Joergen Olsen
-
Publication number: 20180140673Abstract: The invention relates to a derivative of a FGF21 protein having a cysteine residue at a position corresponding to position 167, 169, 170, 171, 172, 173, 174, 175 and in particular position 180 or position 181 of mature human FGF21 and derivatives thereof having a side chain attached to this cysteine. The FGF21 derivatives of the invention display high potency towards the FGF receptors. The invention also relates to pharmaceutical compositions comprising such FGF21 derivatives and pharmaceutically acceptable excipients, as well as the medical use of the FGF21 derivatives.Type: ApplicationFiled: December 21, 2017Publication date: May 24, 2018Applicant: Novo Nordisk A/SInventors: Birgit Wieczorek, Tina Moeller Tagmose, Kristian Sass-Oerum, Birgitte Andersen, Joergen Olsen
-
Patent number: 9956264Abstract: The invention relates to MIC-1 fusion proteins. More specifically it relates to compounds comprising fusion proteins comprising a MIC-1 protein or an analog thereof at the C-terminus of the fusion protein and a functional variant of human serum albumin at the N-terminus of the fusion protein connected via a peptide linker. The compounds of the invention have MIC-1 activity. The invention also relates to pharmaceutical compositions comprising such compounds and pharmaceutically acceptable excipients, as well as the medical use of the compounds.Type: GrantFiled: January 19, 2016Date of Patent: May 1, 2018Assignee: Novo Nordisk A/SInventors: Allan C. Shaw, Charlotte Helgstrand, Michael P. Bastner Sandrini, Sebastian B. Joergensen, Henning Thoegersen, Kristian Sass-Oerum, Sven Hastrup, Kim V. Andersen
-
Patent number: 9895417Abstract: The invention relates to a derivative of a FGF21 protein having a cysteine residue at a position corresponding to position 167, 169, 170, 171, 172, 173, 174, 175 and in particular position 180 or position 181 of mature human FGF21 and derivatives thereof having a side chain attached to this cysteine. The FGF21 derivatives of the invention display high potency towards the FGF receptors. The invention also relates to pharmaceutical compositions comprising such FGF21 derivatives and pharmaceutically acceptable excipients, as well as the medical use of the FGF21 derivatives.Type: GrantFiled: July 7, 2017Date of Patent: February 20, 2018Assignee: Novo Nordisk A/SInventors: Birgit Wieczorek, Tina Moeller Tagmose, Kristian Sass-Oerum, Birgitte Andersen, Joergen Olsen
-
Publication number: 20170354713Abstract: The invention relates to a derivative of a FGF21 protein having a cysteine residue at a position corresponding to position 167, 169, 170, 171, 172, 173, 174, 175 and in particular position 180 or position 181 of mature human FGF21 and derivatives thereof having a side chain attached to this cysteine. The FGF21 derivatives of the invention display high potency towards the FGF receptors. The invention also relates to pharmaceutical compositions comprising such FGF21 derivatives and pharmaceutically acceptable excipients, as well as the medical use of the FGF21 derivatives.Type: ApplicationFiled: July 7, 2017Publication date: December 14, 2017Inventors: Birgit Wieczorek, Tina Moeller Tagmose, Kristian Sass-Oerum, Birgitte Andersen, Joergen Olsen
-
Patent number: 9744213Abstract: The invention relates to a derivative of a FGF21 protein having a cysteine residue at a position corresponding to position 167, 169, 170, 171, 172, 173, 174, 175 and in particular position 180 or position 181 of mature human FGF21 and derivatives thereof having a side chain attached to this cysteine. The FGF21 derivatives of the invention display high potency towards the FGF receptors. The invention also relates to pharmaceutical compositions comprising such FGF21 derivatives and pharmaceutically acceptable excipients, as well as the medical use of the FGF21 derivatives.Type: GrantFiled: March 8, 2017Date of Patent: August 29, 2017Assignee: Novo Nordisk A/SInventors: Birgit Wieczorek, Tina Moeller Tagmose, Kristian Sass-Oerum, Birgitte Andersen, Joergen Olsen
-
Publication number: 20170182124Abstract: The invention relates to a derivative of a FGF21 protein having a cysteine residue at a position corresponding to position 167, 169, 170, 171, 172, 173, 174, 175 and in particular position 180 or position 181 of mature human FGF21 and derivatives thereof having a side chain attached to this cysteine. The FGF21 derivatives of the invention display high potency towards the FGF receptors. The invention also relates to pharmaceutical compositions comprising such FGF21 derivatives and pharmaceutically acceptable excipients, as well as the medical use of the FGF21 derivatives.Type: ApplicationFiled: March 8, 2017Publication date: June 29, 2017Inventors: Birgit Wieczorek, Tina Moeller Tagmose, Kristian Sass-Oerum, Birgitte Andersen, Joergen Olsen
-
Publication number: 20160129083Abstract: The invention relates to MIC-1 fusion proteins. More specifically it relates to compounds comprising fusion proteins comprising a MIC-1 protein or an analogue thereof at the C-terminus of the fusion protein and a functional variant of human serum albumin at the N-terminus of the fusion protein connected via a peptide linker. The compounds of the invention have MIC-1 activity. The invention also relates to pharmaceutical compositions comprising such compounds and pharmaceutically acceptable excipients, as well as the medical use of the compounds.Type: ApplicationFiled: January 19, 2016Publication date: May 12, 2016Inventors: Allan C. Shaw, Charlotte Helgstrand, Michael P. Bastner Sandrini, Sebastian B. Joergensen, Henning Thoegersen, Kristian Sass-Oerum, Sven Hastrup, Kim V. Andersen
-
Patent number: 9272019Abstract: The invention relates to MIC-1 fusion proteins. More specifically it relates to compounds comprising fusion proteins comprising a MIC-1 protein or an analog thereof at the C-terminus of the fusion protein and a functional variant of human serum albumin at the N-terminus of the fusion protein connected via a peptide linker. The compounds of the invention have MIC-1 activity. The invention also relates to pharmaceutical compositions comprising such compounds and pharmaceutically acceptable excipients, as well as the medical use of the compounds.Type: GrantFiled: June 17, 2015Date of Patent: March 1, 2016Assignee: Novo Nordisk A/SInventors: Allan Christian Shaw, Charlotte Helgstrand, Michael Paolo Bastner Sandrini, Sebastian Beck Joergensen, Henning Thoegersen, Kristian Sass-Oerum, Sven Hastrup, Kim Vilbour Andersen